Moderna Inc.

Moderna shares fell more than 5% after Citi judged the valuation unjustified following the sharp price rise and set a price target of $80. Citi analyst Geoff Meacham considers the expectations priced into the stock for expanding personalized cancer vaccines to many tumor types too high and arrives at roughly $100 per share in his discounted cash‑flow analysis. Even under very optimistic success assumptions, a share price around $200 would require annual cancer revenues of about $26 billion, meaning the analyst views the risk‑reward as tilted toward downside. The stock has already risen substantially since the Phase‑3 success of the cancer vaccine Intismeran against melanomas. » Mais em deraktionaer.de

Citi downgraded Moderna to "sell" and, despite raising its price target, saw roughly 60% downside potential, prompting a sharp drop in the stock. A US federal court in Delaware denied Moderna’s motion to dismiss a patent suit by Monsanto/Bayer; Pfizer and BioNTech are also affected and the cases will proceed. Moderna appointed Juan Andres as new COO to support the planned launch of the cancer vaccine Intismeran; the next quarterly report is scheduled for October 29. Whether BioNTech will benefit from Moderna’s headwinds is unclear, since BioNTech is also involved in similar patent disputes and is undergoing operational restructuring. » Mais em finanzen.net

Moderna shares climbed strongly again and are approaching the $200 mark, driven by positive phase-3 results for a skin cancer vaccine developed with Merck. Investors are hoping for further oncology breakthroughs; detailed study data will be presented on October 24 at ESMO. Despite the strong momentum, the roughly $78 billion valuation looks high, especially since revenue and profit from the vaccine will be shared with Merck. » Mais em deraktionaer.de